List of Figures

Figure 1: Classification of PTCL
Figure 2: T-cell neoplasms: organ of origin or involvement and associated chromosomal and genetic alterations.
Figure 3: Representative pathology and PET images
Figure 4: Bone marrow biopsy
Figure 5: Total Incident Cases of PTCL in the 7MM (2019–2032)
Figure 6: Total Incident Cases of PTCL in the US (2019–2032)
Figure 7: Stage-specific Incident Cases of PTCL in the US (2019–2032)
Figure 8: Subtype-specific Incident cases of PTCL in the US (2019–2032)
Figure 9: Total Incident Cases of PTCL in the EU-5 (2019–2032)
Figure 10: Stage-specific Incident Cases of PTCL in the EU-5 (2019–2032)
Figure 11: Subtype-specific Incident Cases of PTCL in the EU-5 (2019–2032)
Figure 12: Total Incident Cases of PTCL in Japan (2019–2032)
Figure 13: Stage-specific Incident Cases of PTCL in Japan (2019–2032)
Figure 14: Subtype-specific Incident cases of PTCL in Japan (2019–2032)
Figure 15: Market Size of PTCL in the 7MM, USD million (2019–2032)
Figure 16: Market Size of PTCL in the US, USD million (2019–2032)
Figure 17: Market Size of PTCL by Therapies in the US, USD million (2019–2032)
Figure 18: Market Size of PTCL in the EU-5, in USD million (2019–2032)
Figure 19: Market Size of PTCL by Therapies in EU-5, USD million (2019–2032)
Figure 20: Market Size of PTCL in Japan, USD million (2019–2032)
Figure 21: Market Size of PTCL by Therapies in Japan, USD million (2019–2032)

List of Tables

Table 1: Summary of PTCL Market, and Epidemiology (2019–2032)
Table 2: Key Events
Table 3: Old and New WHO classifications of PTCLs
Table 4: Subtypes of PTCL
Table 5: Treatment for Patients with Relapsed or Refractory PTCL
Table 6: Total Incident Cases of PTCL in the 7MM (2019–2032)
Table 7: Total Incident Cases of PTCL in the US (2019–2032)
Table 8: Stage-specific Incident Cases of PTCL in the US (2019–2032)
Table 9: Subtype-specific Incident cases of PTCL in the US (2019–2032)
Table 10: Total Incident Cases of PTCL in the EU-5 (2019–2032)
Table 11: Stage-specific Incident Cases of PTCL in the EU-5 (2019–2032)
Table 12: Subtype-specific Incident Cases of Peripheral T-cell Lymphoma in the EU-5 (2019–2032)
Table 13: Total Incident Cases of PTCL in Japan (2019–2032)
Table 14: Stage-specific Incident Cases of PTCL in Japan (2019–2032)
Table 15: Subtype-specific Incident cases of PTCL in Japan (2019–2032)
Table 16: Comparison of marketed drugs for PTCL
Table 17: ADCETRIS, Clinical Trial Description, 2022
Table 18: Comparison Of Emerging Drugs For PTCL
Table 19: Nanatinostat in Combination With Valganciclovir, Clinical Trial Description, 2022
Table 20: Golidocitinib (DZD4205), Clinical Trial Description, 2022
Table 21: Valemetostat Tosylate, Clinical Trial Description, 2022
Table 22: Sugemalimab (CS1001), Clinical Trial Description, 2022
Table 23: Tenalisib, Clinical Trial Description, 2022
Table 24: AZD4573, Clinical Trial Description, 2022
Table 25: Duvelisib, Clinical Trial Description, 2022
Table 26:Tipifarnib, Clinical Trial Description, 2022
Table 27: Tislelizumab (BGB-A317) , Clinical Trial Description, 2022
Table 28: ONUREG (Azacitidine), Clinical Trial Description, 2022
Table 29: AFM13, Clinical Trial Description, 2022
Table 30: Lacutamab/IPH4102, Clinical Trial Description, 2022
Table 31: Tolinapant (ASTX660), Clinical Trial Description, 2022
Table 32: KEYTRUDA (Pembrolizumab), Clinical Trial Description, 2022
Table 33: OPDIVO (nivolumab) + Cabiralizumab, Clinical Trial Description, 2022
Table 34: Market Size of PTCL in the 7MM, USD million (2019–2032)
Table 35: Key Market Forecast Assumptions for Golidocitinib
Table 36: Key Market Forecast Assumptions for ADCETRIS
Table 37: Key Market Forecast Assumptions for Valemetostat
Table 38: Key Market Forecast Assumptions for Sugemalimab
Table 39: Key Market Forecast Assumptions for Tolinapant
Table 40: Key Market Forecast Assumptions for Nanatinostat + Valganciclovir
Table 41: Key Market Forecast Assumptions for Tenalisib
Table 42: Key Market Forecast Assumptions for COPIKTRA
Table 43: Key Market Forecast Assumptions for Lacutamab
Table 44: Key Market Forecast Assumptions for Zarnestra
Table 45: Key Market Forecast Assumptions for AZD4573
Table 46: Key Market Forecast Assumptions for Tislelizumab
Table 47: Key Market Forecast Assumptions for AFM13
Table 48: Key Market Forecast Assumptions for DARVIAS
Table 49: Key Market Forecast Assumptions for HIYASTA
Table 50: Key Market Forecast Assumptions for REMITORO
Table 51: Key Market Forecast Assumptions for XALKORI
Table 52: Market Size of PTCL in the US, USD million (2019–2032)
Table 53: Market Size of PTCL by Therapies in the US, USD million (2019–2032)
Table 54: Market Size of PTCL in the EU-5, in USD million (2019–2032)
Table 55: Market Size of PTCL by Therapies in Germany, USD million (2019–2032)
Table 56: Market Size of PTCL by Therapies in France, USD million (2019–2032)
Table 57: Market Size of PTCL by Therapies in the Italy, USD million (2019–2032)
Table 58: Market Size of PTCL by Therapies in Spain, USD million (2019–2032)
Table 59: Market Size of PTCL by Therapies in the UK, USD million (2019–2032)
Table 60: Market Size of PTCL by Therapies in the EU-5, USD million (2019–2032)
Table 61: Market Size of PTCL in Japan, USD million (2019–2032)
Table 62: Market Size of PTCL by Therapies in Japan, USD million (2019–2032)